Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BRILLIANCE: EDIT-101 in LCA10
NCT03872479Phase 2Unknown
- Sponsor
- Editas Medicine
- Start
- Sep 2019
- Primary completion
- May 2025
- Modality
- Gene Silencing, CRISPR-Cas9, Gene Addition/Replacement
- Countries
- 1
01
Overview
Phase 2, open-label trial of EDIT-101 in Leber congenital amaurosis (LCA) (5 arms), sponsored by Editas Medicine. Primary endpoints: Frequency of Adverse Events related to EDIT-101 at 1 year, Number of participants experiencing procedural related adverse events at 1 year and 1 more. Status: unknown.
02
Drugs
EDIT-101
03
Conditions
Leber congenital amaurosis (LCA)
Beyond the preview
Go deeper on NCT03872479.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03872479.